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Background: Due to physical characteristics, ions like protons or carbon ions can administer the dose to the target
volume more efficiently than photons since the dose can be lowered at the surrounding normal tissue. Radiation
biological considerations are based on the assumption that the α/β value for prostate cancer cells is 1.5 Gy, so that
a biologically more effective dose could be administered due to hypofractionation without increasing risks of late
effects of bladder (α/β = 4.0) and rectum (α/β = 3.9).
Methods/Design: The IPI study is a prospective randomized phase II study exploring the safety and feasibility of
primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique. The
study is designed to enroll 92 patients with localized prostate cancer. Primary aim is the assessment of the safety
and feasibility of the study treatment on the basis of incidence grade III and IV NCI-CTC-AE (v. 4.02) toxicity and/or
the dropout of the patient from the planned therapy due to any reason. Secondary endpoints are PSA-progression
free survival (PSA-PFS), overall survival (OS) and quality-of-life (QoL).
Discussion: This pilot study aims at the evaluation of the safety and feasibility of hypofractionated irradiation of the
prostate with protons and carbon ions in prostate cancer patients in an active beam technique. Additionally, the
safety results will be compared with Japanese results recently published for carbon ion irradiation. Due to the
missing data of protons in this hypofractionated scheme, an in depth evaluation of the toxicity will be created to
gain basic data for a following comparison study with carbon ion irradiation.
Trial registration: Clinical Trial Identifier: NCT01641185 (clinicaltrials.gov)Background
The success of irradiation in patients with localized
prostate cancer correlates with the administered dose
[1-5]. This is well known for patients with an intermedi-
ate risk profile and could also be found recently for pa-
tients with a low risk profile (Gleason score < 7; PSA <
10 ng/ml) [6]. Limitations for using higher doses are
due to an increase of complication rates in particular to* Correspondence: gregor.habl@med.uni-heidelberg.de
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reproduction in any medium, provided the orthe rectum (bleedings, fistula, ulcer), urethra (stenosis)
and bladder (chronic cystitis).
The rate of adverse effects is not only dependent on the
dose but also on the radiation technique used. An earlier
randomized study found that the rectum toxicity was low-
ered significantly when applying 3D-CT based radiation
planning compared with simulator based planning [7]. In a
dose escalating study at the MD Anderson, Pollack and co-
workers found a volume dependency of the rectum toxicity
(rectum volume irradiated with > 70 Gy, toxicity of grade II
or higher after 5 years was 13% or 51% by ≤25% or >25%
rectum volume, respectively [8]. Due to the use of intensity
modulated radiotherapy it is possible to increase the dosesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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parison to 3D conformal radiotherapy, be lowered signifi-
cantly using the same dosage reaching the level obtained
with radiation series giving a total dose of 64–70 Gy. This
monocentric historical comparison showed also a signifi-
cantly higher cure rate [5].
Radiation biological considerations act on the assumption
that the α/β value (tissue specific constant specifying the
tissues’ sensitivity for the possibility of developing a late tox-
icity if single doses are increased) of the prostate cancer
cells is low [9]. Since the assumed α/β value of 1.5 Gy for
prostate cancer cells is clearly below the α/β values of blad-
der (α/β value 4.0) and rectum (α/β value 3.9), a radiation
biological more effective dose could be administered due to
increased single doses without increasing risks of late ad-
verse effects. At the same time, the overall treatment time
is shortened. This radiation biological hypothesis was con-
firmed in a study of 770 patients receiving a total dose of
70 Gy in 28 fractions, single doses of 2.5 Gy where bio-
chemical recurrence free survival was 83% after 5 years for
all risk groups, 95% for the low risk group with only 2%
acute and late grade 3 or higher toxicity [2].
Due to physical characteristics, ions like protons or car-
bon ions can administer the dose to the target volume
more efficiently than photons since the dose can be low-
ered to the surrounding normal tissue. However, parts of
the risk organs remain in the target volume: base of blad-
der, urethra and the facing wall of the rectum. The toler-
ance dose of the urethra, which is in the center of the
target volume, is >85 Gy. A prospective study with a frac-
tion scheme of 48 × 1.8 Gy = 86.4 Gy reported the appear-
ance of urethral strictures in <3% of the patients [10]. For
both, the bladder and rectum, studies found a high volume
effect. The TD 5/5 for radiation of 2/3 of the bladder is 80
Gy, whereas it is 65 Gy for radiation of the whole bladder
[11]. For the rectum, a high volume effect is known as well
[12]. With ion radiation, it is possible to spare especially
the posterior rectum wall in comparison to photon radi-
ation, so potentially receiving also a more efficient regen-
eration of the anterior rectum wall. For proton irradiation,
we know the data of the retrospective analysis of Loma
Linda [13], as well as the randomized study of Boston, in
which proton boost to a TD of 79.2 Gy vs. 70.2 Gy was
used after a radiation of photons. The authors showed a
significant advantage for high doses with an acceptable oc-
currence of adverse effects (2% acute and chronic toxicity <
of CTC grade 3 or higher) [6].
Due to its mass, carbon ions have a higher biological ef-
ficacy than protons with comparable dose profile. Several
trials using carbon ions in a dose escalating manner were
performed by the group of researchers in Chiba/Japan. A
total of 176 patients were treated with a dose of 20 × 3.3
GyE. The 5-year biochemical recurrence free survival rate
was up to 83.2% for all patients and 100% for patients withlow risk prostate cancer. No late toxicity of CTC grade 3
or higher was found [3]. However, the region of the anter-
ior rectum wall was only strained to 50-90% of the dose.
All published studies of irradiation of the prostate with
ions use a passive beam modulation. Currently developed
is ion radiation with active beam modulation and raster
scan technique [14]. The target volume is radiated point-
by-point in contrast to the radiation in layers in passive
beam modulation. The advantage of this method is the
lower production of neutrons, and as such the lower risk
of the occurrence of secondary malignancies. Despite the
more exact dose application, the passive beam modulation
has no advantage in developing secondary cancer com-
pared to IMRT irradiation [1].
In an initial study in our department, we tested the
feasibility and safety of the active beam modulation of
carbon ion irradiation of the prostate. We used a carbon
ion boost of 6 × 3 GyE in combination with an IMRT
photon radiation of 30 × 2 Gy. An interim analysis
showed a good response rate and no increased toxicity
[15]. On the other hand, we could not identify data for
hypofractionated irradiation of the prostate with pro-
tons so far.
To spare the rectum additionally and to consider the
movement of the prostate during the irradiation [16], an
absorbable gel can be injected between the rectum and the
prostate. In a prospective multi-center trial, we could show
that the rectum dose could be significantly lowered using
this gel that established a stable gap of 7–10 mm between
rectum and prostate for approximately 6 months [17,18].
The planned IPI study is a prospective randomized
phase II study exploring the safety and feasibility of pri-
mary hypofractionated irradiation of the prostate with
protons and carbon ions in a raster scan technique and is
planned to enroll 92 patients with localized prostate can-
cer. Primary endpoint is the portion of patients to whom
the study treatment can be safely applied (i.e. without
grade III and IV NCI-CTC-AE (v. 4.02) toxicity) and/or
without dropout from the planned therapy due to any rea-
son (rate of safety and feasibility). Secondary endpoints
are PSA-progression free survival (PSA-PF, overall survival
(OS) and quality-of-life (QoL).
Methods/Design
Trial organization/coordination
The IPI study is designed as an open-label, prospective,
single-center, randomized two-armed (proton vs. carbon
ion irradiation) pilot study evaluating the safety and feasi-
bility of hypofractionated irradiation of the prostate with
protons and carbon ions in prostate cancer patients in an
active beam technique designed by the study initiators of
the Department of Radiation Oncology of the University
of Heidelberg. The two study arms are defined by treat-
ment with arm A (protons at 66 Gy in 20 fractions) and
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initiation, ethical consent was obtained from the ethics
committee of the University of Heidelberg, Germany
(Medical Faculty). The number of the ethics committee of
Heidelberg (Institutional Review board) is S-298/2011. All




 Histologically confirmed localized prostate cancer
with histological classification according to the
Gleason score (GS)
 Risk of lymph node involvement < 15% referred to the
Yale formula on the basis of T-stage, Gleason score
and PSA level (without antihormonal therapy) [4]
Risk %ð Þ ¼ GS−5ð Þ  PSA=3þ 1:5 Tð Þ;with T
¼ 0; 1 and 2 for cT1c; cT2a and cT2b=cT2c
 PSA level (without antihormonal therapy)
 Age between 40 and 80 years of age
 Karnofsky index ≥ 70%
 Signed written informed consent
Exclusion criteria:
 Previous radiotherapy in the pelvic area
 Distant metastases (stage IV)
 Lymphogenous metastases
 Hip implants or other metal prosthesis at the height
of the prostate
 Concurrent participation in other clinical studies,
which could influence the results of the respective
study
 Active medical implants e.g. pacemaker, defibrillator,
which are excluded for ion irradiation
Work-up
Should a patient meet the trial conditions, information
about participation in the study including potential risks
and benefits is given to the patient. As soon as written
consent is obtained, patients can be included into the
IPI trial and all required documentation will be pro-
vided by the study center (Studienzentrale Klinische
Radiologie, Abt. Strahlentherapie und Radioonkologie,
INF 400. 69120 Heidelberg). Before start of treatment
an examination including the medical history is taken
and the staging examinations where necessary are docu-
mented. Before radiation the SpaceOAR (Augmenix,
Waltham, MA, USA) is injected at the Department of
Urology of the University of Heidelberg. Additionally, a
MRI for morphological and functional imaging isconducted. Also the PSA level and QoL (standardized
questionnaires EORTC QLQ-C30 and QLQ-PR25) are de-
termined before irradiation. Each patient receives a RT-
planning CT-scan in an individually-adjusted precision
immobilisation devices (ProStep, ITV, Innsbruck, Austria).
During radiation therapy the patient is supervised by a
radiooncologist and clinical symptoms and toxicity (NCI-
CTCAE v. 4.02) are documented. Where necessary, a sup-
portive medication is initiated or adapted. The blood count
is controlled every week. Morphological and functional
MRI examinations are scheduled for midterm of the radi-
ation therapy and during follow up visits (see below). As-
sessment of NCI -CTC toxicity, QoL as well as functional
MRI imaging should take place (Table 1). Follow-up ap-
pointments are scheduled.
The post-treatment examinations include measuring the
PSA level 6 weeks after the end of treatment and after-
wards in three months intervals. It’s important that the
PSA level is always determined in the same laboratory to
avoid deviations due to differential measurement methods.
Additionally, a radiooncological post-treatment examin-
ation takes place 6 weeks, 6, 12, 18 and 24 months after
the end of treatment including a functional MR imaging.
Acute and late toxicity of the irradiation will be assessed
on each of the appointments and documented. QoL will
be collected at week 6 and after 6 and 24 months. Subse-
quent to the two years, patient will be after treated accord-
ing to the current requirements of the guidelines of
radiation protection. We will contact the patients at least
once a year to ask for PSA-levels and side effects.
Radiation therapy
Definition of target volumes and risk organs
The clinical target volume (CTV) is defined as the pros-
tate and the inferior 2/3 of seminal vesicles plus a margin
of 2 mm. The planning target volume (PTV) is defined as
the CTV plus 7 mm in lateral direction (beam direction)
and 5 mm anterior-posterior as well as in inferior-superior
direction. An extra target volume for the rectum (PTV-
Rectum) is defined as intersection volume between PTV
and rectum. As risk organs are defined rectum, bladder,
femoral heads and intestine.
Definition of the dosage
95% of the PTV should receive 66 Gy in 20 fractions (5–6
fractions a week) in four weeks. Equivalent doses of the fol-
lowing risk organs (in single doses of 2 Gy) are: for the
prostate (α/β = 1.5 Gy) 90.5 Gy, for the bladder (α/β = 4.0
Gy) 80.3 Gy and for the urethra (α/β = 4.5 Gy) 79.2 Gy.
The maximal dose for the PTV-Rectum should not exceed
60 Gy. Therefore, the equivalent dose (in a single dose of 2
Gy) is 69.2 Gy (α/β = 3.9 Gy). Other DVH (dose-volume-
histogram) constraints are: for the bladder V47 < 30% and
V63 < 10%, for the rectum V47 < 30% and V60 < 10%.
Table 1 Course of the IPI study









+6 weeks +6 months +12 months +18 months +24 months
• Spacer injection • Documentation of toxicities





• Documentation of PSA level
• Morphological &
functional MRI
• Control of blood counts • QoL • Documentation of toxicities
• Planning CT • Functional MRI in week 3 • Functional MRI • Functional MRI
• PSA level • QoL (+6 weeks, +6 months and +24 months)
• QoL
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The recruitment of patients is carried out within two
years. The analysis of study results concerning the pri-
mary end point (safety and feasibility) will start 6 weeks
after the end of treatment of the last patient. Study end
point is 24 months after the end of treatment of the last
patient. Total study duration is 4 years.
Evaluation of safety
In radiooncology we differentiate between acute and
chronic adverse effects. Acute events are defined to arise
within 6 weeks after end of treatment. Data of acute and
chronic toxicities are collected during and after treat-
ment on the basis of the NCI-CTC-AE (National Cancer
Institute Common Terminology Criteria for Adverse
Events) version 4.02 classified into
 Grade 1 = mild; clinical observation; intervention
not indicated
 Grade 2 = moderate; minimal, local intervention
indicated
 Grade 3 = severe; hospitalization; not immediately
life-threatening
 Grade 4 = life-threatening
 Grade 5 = death related to AE
A safe feasibility is defined in this study if no grade 3
toxicity or higher is occurring from beginning of therapy
to 6 weeks after the end of treatment without drop out
from treatment (see next section). The time till the pres-
entation of a > grade 2 toxicity is another, but secondary,
endpoint. All toxicities > grade 2 must be reported the
safety board.
Statistics
The primary objective of the pilot study is to demonstrate
the safety and feasibility of the study treatment on the
basis of the incidence of grade 3 or higher NCI-CTC AE
toxicity and/or a termination of the planned therapy made
of any reason. This secure feasibility (SF) is given when
from the start of radiation therapy for up to 6 weeks aftercompletion, not any grade 3 or higher toxicity occurred
(including toxicity-related death, grade 5) and if the ther-
apy was not stopped due to any other reason, e.g. due to
any toxicity (grade 1–4). Taking into account the pub-
lished very favorable results, the percentage of failure is as-
sumed to be very small and is set to 2.5%, such that the
target rate of the SFR was set to 97.5%.
Two co-primary study hypotheses are derived from the
questions: a) Is the toxicity of carbon ion irradiation (arm
B) non-inferior compared to standard radiation? b) Is the
toxicity of the proton irradiation (arm A) non-inferior
compared to standard?
Formerly the two hypotheses are indepently test using
the nullhypothesis Ho: SFR < 87.5% versus H1: SFR ≥
97.5%, respectively, for each arm. The decision on the
study success is defined for each arm separately. Assuming
a type I error of alpha =10% and a power of at least 90%
the study needs to recruit per arm n = 41 evaluable pa-
tients. This sample size calculation based on the PASS
program (Number Cruncher Statistical Systems, October
24 2005, http://www.ncss.com/) and the procedure of
Blackwelder (1982) for non-inferiority trials [19]. To re-
place drop out cases (drop out between consent and the
start of treatment or for any other reason), per arm n = 46
patients will be recruited into the study such that a total
of N = 92 patients is required. Randomization is per-
formed in blocks of lenths 4 stratified by one dichoto-
mized factor (presence/absence of anti-hormonal therapy
during radiation). GS and PSA values will be used for de-
fining post-randomization strata. The analysis of the pri-
mary endpoint will be performed by means of one-sample
binomial testing. As describing parameters the 97.5% and
the 90% confidence limits of the SFR are calculated. NCI-
CTC adverse events will be evaluated. PSA-PSF, OS and
duration of treatment or study participation are described
by means of empirical survival functions. QoL will be eval-
uated using EORTC QLQ-C-30 guidelines. No formal in-
terim analysis is planned, however, recruitment will be put
on hold when the number of failures is larger than 4 in
one arm for a discussion of the future of the study in the
study team and the Institutional Review Board.
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With the conducted study we want to gain basis data of
hypofractionated irradiation of the prostate with both, car-
bon ions and protons in terms of controlled clinical study.
Referring to these experiences a confirmatory randomized
study comparing carbon ion and proton irradiation will be
planned. Hypofractionated carbon ion irradiation is consid-
ered as therapy standard since data from Japan are existing,
however, not conducted with the raster scan technique.
These data serve as historical controls to plan and to evalu-
ate this pilot study regarding safety and feasibility of both
planned study arms. Primary endpoint is the evidence of the
safety and feasibility of the study treatment on the basis of
incidence grade III and IV NCI-CTC-AE (v. 4.02) toxicity
and/or the dropout of planned therapy due to any reason.
Both study treatments (arm A: protons; arm B: carbon
ions) will be tested separately, but randomized, in a non-
inferiority trial for the primary endpoint toxicity since the
efficacy of both radiotherapeutical approaches is compar-
able. The non-inferiority/inferiority is quantified separately
by means of the historical control. The question which
arm has the advantageous toxicity is evaluated explor-
atively to plan consecutively a confirmatory study for a full
evaluation of efficacy and feasibility of hypofractionated ir-
radiation of the prostate with protons and carbon ions in
prostate cancer patients in an active beam technique.
For each of both arms the same non-inferior level of tox-
icity is chosen and with a width of 10% fits the purpose of a
pilot study similarly as the chosen statistical type I error
probability of 10%. The calculation of the number of cases
occurs on the basis of the both non-inferior questions in
comparison to the standard calibrated at the toxicity rate of
maximal 2.5% from the current standard (supported by the
Japanese results with no reported toxicity).
Randomization will guarantee comparability of both
study arms by a balanced patient population in both groups
but is not intended for a confirmatory comparison of both
arms. Parallel group comparisons are conducted as second-
ary comparisons.
Aim of the pilot study is the evaluation of the safety and
feasibility of hypofractionated irradiation of the prostate
with protons and carbon ions in prostate cancer patients
in an active beam technique. Additionally, the results of
the carbon ion irradiation of the Japanese study are com-
pared in terms of toxicity. A toxicity analysis of the same
fractionation scheme with protons will be opposed to the
results of the carbon ion irradiation. PSA-PFS, OS and
QoL are secondary outcome measures.
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